Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Bayer AG
Woman and Man Max 99 years
Bayer AG
Update Il y a 5 ans
A study to test the safety and effectiveness of Bay 41-6551 as additional therapy to standard of care antimicrobial treatment in patients who have Gram-Negative Pneumonia and are intubated and mechanially ventilated
To demonstrate that as adjunctive therapy to IV antibiotics, BAY 41-6551 400 mg (amikacin as free base) administered as an aerosol by the PDDS Clinical every 12 hours is safe and more effective than p...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Bayer AG
Update Il y a 5 ans
Efficacy and safety of riociguat in patients with high blood pressure in the blood vessels of the lungs associated with interstitial pneumonias of unknown cause
To evaluate the efficacy and safety of 26-weeks of treatment with riociguat vs. placebo in patients with symptomatic PH associated with IIP
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Bayer AG
Update Il y a 5 ans
Efficacy and safety of two different aflibercept regimens in subjects with nAMD
To compare the efficacy of 2 mg aflibercept administered by two different intravitreal (IVT) treatment regimens to subjects with nAMD.
Country
None
organs
None
Specialty
None
unknown
More information
Woman Max 99 years
Bayer AG
Update Il y a 5 ans
Multicenter, randomized and single-blind (group assigned by chance and unknown to study subjects), comparator-controlled study with all groups running in parallel to investigate the pharmacological effects, drug blood levels and safety of an intrauterine system releasing the study drug BAY 1007626 as compared to Mirena and Jaydess in healthy pre-menopausal women treated for 90 days to determine the study drug dose for further development Klinische Prüfung zur Bestimmung pharmakologischer Eigenschaften, der Wirkstoffkonzentration im Blut und der Sicherheit einer BAY1007626 freisetzenden Gebärmutterspirale im Vergleich mit Mirena und Jaydess bei gesunden, jungen Frauen über 90 Tage zur Bestimmung der Dosis für die weitere Arzneimittelentwicklung
The primary objective of this study is to investigate local and systemic effects of BAY 1007626 on: – Number of bleeding and spotting days, – Endometrial histology, – Ovulation (as surrogate for sy...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Bayer AG
Update Il y a 5 ans
Single-dose study testing rivaroxaban granules to be diluted into an oral suspension in children from 2 months to 12 years with previous blood clot
To characterize the pharmacokinetic profile of rivaroxaban administered as granules for oral suspension
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Bayer AG
Update Il y a 5 ans
A study to investigate the safety and efficacy of a six month oral treatment with a twice daily dose of BAY 1142524 in comparison to placebo in patients with reduced left-ventricular ejection fraction after acute myocardial infarction. Studie hodnotící bezpečnost a účinnost 6měsíční léčby přípravkem BAY 1142524 podávaného perorálně dvakrát denně, v porovnání s placebem, u pacientů se sníženou ejekční frakcí levé komory po akutním infarktu myokardu
The primary objective of this study is to determine efficacy of BAY 1142524 by investigating the changes in LVEF, EDVI, and ESVI from baseline to 6 months after treatment with 25 mg of BAY 1142524 BID...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Bayer AG
Update Il y a 5 ans
Efficacy and safety of rivaroxaban in reducing the risk of major thrombotic vascular events in subjects with peripheral artery disease undergoing peripheral revascularization procedures of the lower extremities
To evaluate whether rivaroxaban added to acetylsalicylic acid (ASA) is superior to ASA alone in reducing the risk of major thrombotic vascular events (defined as myocardial infarction (MI), ischemic s...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Bayer AG
Update Il y a 5 ans
Rivaroxaban for treatment in venous thrombosis in children
The primary efficacy objective is: To assess the incidence of symptomatic recurrent venous thromboembolism The principal safety objective is: To assess the incidence of overt major and clinica...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Bayer AG
Update Il y a 5 ans
Efficacy and safety of finerenone in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease
Demonstrate whether, in addition to standard of care, finerenone is superior to placebo in delaying the time to first occurrence of cardiovascular mortality and morbidity in subjects with type 2 diabe...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Bayer AG
Update Il y a 5 ans
An open-label, uncontrolled and non-blinded study to assess different doses of a new drug (Bay 63-2521), given orally as multiple ascending doses, to evaluate if it is safe and can help to improve the well-being of patients with interstitial lung disease associated pulmonary hypertension by lowering the pulmonary artery blood pressure
Main objective of the trial is to investigate the safety and tolerability of a 12-week treatment with BAY 63-2521 of patients with pulmonary hypertension due to intestinal lung disease (ILD idiopathic...
Country
None
organs
None
Specialty
None
unknown
More information
1
2
3
4
Next